fbpx
  • Home
  • Search Results

Research Studies

UNC-Chapel Hill Division of Hematology

28 studies match your search
Open

Birth Control and Blood Clotting Study

Are you considering starting birth control and are not on it yet? Help us learn how birth control affects risk of blood clots! We are looking to learn more about blood clot risk when women with sickle cell disease start birth control, and we need healthy women for comparison. This will involve a survey and blood draw at the visit to start birth control and then 3 months afterward. A small compensation is provided.

Age & Gender
  • 15 years ~ 55 years
  • Female
Study Interest
  • Blood Conditions
  • Healthy Volunteer or General Population
  • Sexual and/or Reproductive Health
  • Women's Health
Not currently enrolling

Testing the Usability of a Patient-Centered Tool

We are developing a computer-based tool for people who have cancers of the blood, bone marrow, and lymph nodes. This tool will help us understand what is most important to patients when it comes to the results of their treatment. We are looking for healthy volunteers (those without cancer) to help us test the usability of this tool.

Age & Gender
  • 21 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
Open

Multicenter study to learn more about brain avms and bleeding in people with Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT) is a condition that causes abnormal blood vessels to form. This goal of this study is to look at people who have HHT, with and without brain arteriovenous malformations (BAVMs). The purpose of this study is to learn more about brain AVMs (BAVMs) and bleeding in patients with HHT. We plan to study risk factors for rupture of BAVMs and also for other bleeding and features of HHT disease, including primarily genetics and imaging characteristics of the BAVMs. We hope that knowledge about risk factors will help improve the care and management of HHT patients.

Age & Gender
  • 0 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

GRNDaD

To have a well phenotyped cohort of people with sickle cell disease in order to examine risk factors for end organ disease through the creation of a multi-site registry and to develop a repository for the long-term storage of patient samples (whole blood, peripheral blood, serum) along with corresponding demographic and clinical information to allow for clinical and laboratory correlations.

Age & Gender
  • 0 years ~ 0 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Minority Health
  • Pain
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Mismatched Unrelated Donor

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

Age & Gender
  • 1 years ~ 66 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
  • Transplant
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Identifying challenges and stressors related to accessing central venous catheters (CVCs) for treatment infusions: a pilot study

The purpose of this research study is to improve safety measures and reduce stressors associated with lumen hub-clave seizures when caring for patients with CVCs. The primary outcome of the pilot study is to document the types and frequency of workarounds employed, current disinfection techniques, and the stressors of those caring for and accessing CVCs.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Stomach, Digestion and Gut Health
  • Immune System/Infections
  • Opinions and Perceptions
  • and 3 more
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

ASH Research Collaborative Data Hub Protocol: A Multi-Center Data Hub of Individuals Living with Hematologic Disease

To further the scientific knowledge base for the diagnosis, understanding, and management of sickle cell disease (SCD) by assembling data collected in routine clinical care and closed clinical trials. This umbrella Data Hub Protocol will permit the creation of a patient-level data repository obtained from individuals, or the records of individuals, with SCD thereby collecting key information and identifying gaps that will help advance SCD treatment and research.

Age & Gender
  • 0 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Page 1 of 7 Version 2 | April 14, 2020 ASH Research Collaborative Data Hub Protocol A Multi-Center Data Hub of Individuals Living with Hematologic Disease

The ASH Registry d/b/a the ASH Research Collaborative (ASH RC), is a non-profit organization established by the American Society of Hematology (ASH) in 2018 that aims to improve the lives of those affected by blood diseases by fostering collaborative partnerships to accelerate progress in hematology. The foundation of the ASH RC is its Data Hub, a technology platform that facilitates the exchange of information by aggregating in one place, and making available for inquiry, research-grade data on hematologic diseases. In 2019, ASH RC launched its first research initiative, the Sickle Cell Disease (SCD) Clinical Trials Network (CTN), with the goal of optimizing SCD clinical research operations. As part of its core functions, the SCD-CTN leverages the Data Hub to collect key information and identify gaps that will help advance SCD research and treatment. The primary goal of the Data Hub is to further the scientific knowledge base for the diagnosis, understanding,

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Leukemia, Lymphoma, Multiple Myeloma)
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (CPX-351) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Can we lower the chances of your acute myeloid leukemia (AML) growing by adding a drug to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your AML. The usual approach is defined as care most people get for AML.

Age & Gender
  • 18 years ~ 75 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Testing CC-486 Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, ransformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements

To determine if patients that are 75 years of age or older who were recently diagnosed with DLBCL be able to take the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for at least 4 cycles of therapy (a cycle = 21 days; 4 cycles is 12 weeks) without significantly more side effects than patients taking the standard drug therapy alone; have longer, shorter, or the same amount of time without the disease getting worse (progression) than patients taking the standard drug therapy alone; live longer, live the same amount of time, or live a shorter amount of time than patients taking the standard drug therapy alone. This study is being done to find out if this approach is better or worse than the usual approach for the DLBCL. The usual approach is defined as care most people get for DLBCL.

Age & Gender
  • 75 years ~ 99 years
  • Male, Female
Study Interest
  • Aging
  • Cancer (Lymphoma)
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research